{"id":2896,"date":"2024-07-18T15:04:30","date_gmt":"2024-07-18T15:04:30","guid":{"rendered":"https:\/\/capahc.com\/?p=2896"},"modified":"2025-01-14T17:18:57","modified_gmt":"2025-01-14T17:18:57","slug":"hep-c-new-treatment-access-quebec","status":"publish","type":"post","link":"https:\/\/capahc.com\/en\/hep-c-new-treatment-access-quebec\/","title":{"rendered":"Hep C new treatment access Quebec"},"content":{"rendered":"<h2 class=\"wp-block-heading\" id=\"h-hepatite-c-acces-elargi-aux-traitements-au-quebec\">Hepatitis C: Expanded access to treatment in Quebec<\/h2>\n\n\n\n<p data-block-type=\"core\">Good news for patients living with <a href=\"https:\/\/capahc.com\/en\/quest-ce-quune-hepatite\/\">hepatitis<\/a> C, finally a<br>greater access to treatment in Quebec :<\/p>\n\n\n\n<ul class=\"wp-block-list\" data-block-type=\"core\">\n<li data-block-type=\"core\">All patients living with chronic hepatitis C, genotype 1 and fibrosis stage F2-F4 will have access to <a href=\"https:\/\/www.harvoni.com\/\">Harvon<\/a><a href=\"https:\/\/www.harvoni.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">i<\/a> and <a href=\"https:\/\/medbroadcast.com\/drug\/getdrug\/holkira-pak\" target=\"_blank\" rel=\"noreferrer noopener\">Holkira Pak<\/a> from March 24, 2016.<\/li>\n\n\n\n<li data-block-type=\"core\">All patients with genotype 1, at fibrosis stage F1 and presenting a poor prognosis factor will also have access to the product from March 24.<\/li>\n<\/ul>\n\n\n\n<p data-block-type=\"core\"><\/p>\n\n\n\n<div class=\"wp-block-stackable-image stk-block-image stk-block stk-4863f3d\" data-block-id=\"4863f3d\"><style>.stk-4863f3d .stk-img-figcaption{text-align:center !important;font-size:16px !important;}.stk-4863f3d {margin-bottom:50px !important;}.stk-4863f3d .stk-img-wrapper{height:300px !important;--stk-gradient-overlay:0.1 !important;}:where(.stk-hover-parent:hover,  .stk-hover-parent.stk--is-hovered) .stk-4863f3d .stk-img-wrapper img{transform:scale(1.1) !important;}.stk-4863f3d .stk-img-wrapper::after{background-color:#070803 !important;}:where(.stk-hover-parent:hover,  .stk-hover-parent.stk--is-hovered) .stk-4863f3d .stk-img-wrapper::after{background-color:#000000 !important;}.stk-4863f3d .stk-img-wrapper::before{--stk-gradient-overlay:0.7 !important;}:where(.stk-hover-parent:hover,  .stk-hover-parent.stk--is-hovered) .stk-4863f3d .stk-img-wrapper{--stk-gradient-overlay:0.7 !important;}@media screen and (max-width: 1023px){.stk-4863f3d .stk-img-figcaption{font-size:16px !important;}}<\/style><figure><span class=\"stk-img-wrapper stk-image--shape-stretch\"><img loading=\"lazy\" decoding=\"async\" class=\"stk-img wp-image-2897\" src=\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp\" width=\"708\" height=\"338\" alt=\"Harvoni is a direct-acting antiviral medication used to treat hepatitis C. It is a combination of two medications, sofosbuvir and ledipasvir\" srcset=\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp 708w, https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers-300x143.webp 300w, https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers-18x9.webp 18w\" sizes=\"auto, (max-width: 708px) 100vw, 708px\" \/><\/span><figcaption class=\"stk-img-figcaption\">Harvoni is a direct-acting antiviral medication used to treat hepatitis C<\/figcaption><\/figure><\/div>\n\n\n\n<p data-block-type=\"core\">Poor prognostic factors include<\/p>\n\n\n\n<ul class=\"wp-block-list\" data-block-type=\"core\">\n<li data-block-type=\"core\">Severe extrahepatic manifestations (type 2 or 3 cryoglobulinemia with organ damage, vasculitis, B-cell non-Hodgkin's lymphoma, nephropathy).<\/li>\n\n\n\n<li data-block-type=\"core\">Co-infection (HIV, HBV)<\/li>\n\n\n\n<li data-block-type=\"core\">Other liver disease (non-alcoholic steatohepatitis),<\/li>\n\n\n\n<li data-block-type=\"core\">type 2 diabetes<\/li>\n\n\n\n<li data-block-type=\"core\">Advanced cutaneous porphyria<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-les-patients-f3-f4-ont-deja-acces-a-ces-nouveaux-medicaments-depuis-le-24-juillet-2015\">F3\/F4 patients have already had access to these new drugs since July 24, 2015.<\/h3>\n\n\n\n<p data-block-type=\"core\">This expanded access to treatment in Quebec is the result of recommendations made by the<a href=\"https:\/\/www.inesss.qc.ca\/en\/index.html\" target=\"_blank\" rel=\"noreferrer noopener\">INESSS<\/a> to reimburse Harvoni and Holkira Pak. This will be done on a sequential basis over 6 years, with specific conditions, to ensure that citizens have reasonable and equitable access to healthcare.<\/p>\n\n\n\n<p data-block-type=\"core\">We are very happy for all the patients concerned. See the new prescription drug regulations.<\/p>\n\n\n\n<p data-block-type=\"core\">Laurence Mersilian for Capahc - Expanded access to treatment in Quebec<\/p>\n\n\n\n<p data-block-type=\"core\">Published on March 18, 2016 by CAPAHC<br><br>*First and foremost, this significant advance in the treatment of hepatitis C in Quebec is part of a broader trend towards improved access to direct-acting antivirals (DAAs) in Canada. Indeed, these drugs, such as Harvoni and Holkira Pak, offer cure rates close to 100% with minimal side effects. Treatment duration is reduced to 8 or 12 weeks. Nevertheless, although access to these treatments has improved, challenges remain. In particular, reimbursement for DAAs remains complex and can vary from province to province. It is also important to note that Health Canada approval does not guarantee immediate access to all patients.<\/p>","protected":false},"excerpt":{"rendered":"<p>H\u00e9patite C : Acc\u00e8s \u00e9largi aux traitements au Qu\u00e9bec Bonne nouvelle pour les patients vivant avec l&rsquo;h\u00e9patite C, finalement unacc\u00e8s \u00e9largi aux traitements au Qu\u00e9bec : Harvoni est un m\u00e9dicament antiviral \u00e0 action directe utilis\u00e9 pour traiter l&rsquo;h\u00e9patite C. Les facteurs de mauvais pronostic sont Les patients F3\/F4 ont d\u00e9j\u00e0 acc\u00e8s \u00e0 ces nouveaux m\u00e9dicaments [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2896","post","type-post","status-publish","format-standard","hentry","category-nouvelles-articles"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.0 (Yoast SEO v26.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hep C new treatment access Quebec - CAPAHC<\/title>\n<meta name=\"description\" content=\"Acc\u00e8s \u00e9largi aux traitements de l&#039;h\u00e9patite C au Qu\u00e9bec. Harvoni et Holkira Pak rembours\u00e9s. Taux de gu\u00e9rison \u00e9lev\u00e9s. Traitement plus court.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/capahc.com\/en\/hep-c-new-treatment-access-quebec\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hep C new treatment access Quebec\" \/>\n<meta property=\"og:description\" content=\"Acc\u00e8s \u00e9largi aux traitements de l&#039;h\u00e9patite C au Qu\u00e9bec. Harvoni et Holkira Pak rembours\u00e9s. Taux de gu\u00e9rison \u00e9lev\u00e9s. Traitement plus court.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/capahc.com\/en\/hep-c-new-treatment-access-quebec\/\" \/>\n<meta property=\"og:site_name\" content=\"CAPAHC\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CAPAHC\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-18T15:04:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-14T17:18:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/capahc.com\/#\/schema\/person\/422fdb9132c4ee6be40a85ed2d59f15e\"},\"headline\":\"Hep C new treatment access Quebec\",\"datePublished\":\"2024-07-18T15:04:30+00:00\",\"dateModified\":\"2025-01-14T17:18:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/\"},\"wordCount\":398,\"publisher\":{\"@id\":\"https:\/\/capahc.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp\",\"articleSection\":[\"NOUVELLES ET ARTICLES\"],\"inLanguage\":\"en-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/\",\"url\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/\",\"name\":\"Hep C new treatment access Quebec - CAPAHC\",\"isPartOf\":{\"@id\":\"https:\/\/capahc.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp\",\"datePublished\":\"2024-07-18T15:04:30+00:00\",\"dateModified\":\"2025-01-14T17:18:57+00:00\",\"description\":\"Acc\u00e8s \u00e9largi aux traitements de l'h\u00e9patite C au Qu\u00e9bec. Harvoni et Holkira Pak rembours\u00e9s. Taux de gu\u00e9rison \u00e9lev\u00e9s. Traitement plus court.\",\"breadcrumb\":{\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#primaryimage\",\"url\":\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp\",\"contentUrl\":\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/capahc.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hep C new treatment access Quebec\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/capahc.com\/#website\",\"url\":\"https:\/\/capahc.com\/\",\"name\":\"CAPAHC\",\"description\":\"Votre R\u00e9f\u00e9rence pour l\u2019H\u00e9patite C au Qu\u00e9bec\",\"publisher\":{\"@id\":\"https:\/\/capahc.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/capahc.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/capahc.com\/#organization\",\"name\":\"CAPAHC - Centre Associatif Polyvalent d\u2019Aide H\u00e9patite C\",\"url\":\"https:\/\/capahc.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capahc.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/Logo-CAPAHC-.webp\",\"contentUrl\":\"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/Logo-CAPAHC-.webp\",\"width\":672,\"height\":133,\"caption\":\"CAPAHC - Centre Associatif Polyvalent d\u2019Aide H\u00e9patite C\"},\"image\":{\"@id\":\"https:\/\/capahc.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CAPAHC\",\"https:\/\/ca.linkedin.com\/company\/capahc\",\"https:\/\/www.youtube.com\/channel\/UCBZzrLKLNGiWTqCuQEY95xA\",\"https:\/\/www.instagram.com\/capahcorg\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/capahc.com\/#\/schema\/person\/422fdb9132c4ee6be40a85ed2d59f15e\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/capahc.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/cb4c1630c77eb892adbde4044bcc33d61d3408dafde03675d45b78038e160d85?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/cb4c1630c77eb892adbde4044bcc33d61d3408dafde03675d45b78038e160d85?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/capahc.com\"],\"url\":\"https:\/\/capahc.com\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hep C new treatment access Quebec - CAPAHC","description":"Acc\u00e8s \u00e9largi aux traitements de l'h\u00e9patite C au Qu\u00e9bec. Harvoni et Holkira Pak rembours\u00e9s. Taux de gu\u00e9rison \u00e9lev\u00e9s. Traitement plus court.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/capahc.com\/en\/hep-c-new-treatment-access-quebec\/","og_locale":"en_US","og_type":"article","og_title":"Hep C new treatment access Quebec","og_description":"Acc\u00e8s \u00e9largi aux traitements de l'h\u00e9patite C au Qu\u00e9bec. Harvoni et Holkira Pak rembours\u00e9s. Taux de gu\u00e9rison \u00e9lev\u00e9s. Traitement plus court.","og_url":"https:\/\/capahc.com\/en\/hep-c-new-treatment-access-quebec\/","og_site_name":"CAPAHC","article_publisher":"https:\/\/www.facebook.com\/CAPAHC","article_published_time":"2024-07-18T15:04:30+00:00","article_modified_time":"2025-01-14T17:18:57+00:00","og_image":[{"url":"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp","type":"","width":"","height":""}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#article","isPartOf":{"@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/"},"author":{"name":"admin","@id":"https:\/\/capahc.com\/#\/schema\/person\/422fdb9132c4ee6be40a85ed2d59f15e"},"headline":"Hep C new treatment access Quebec","datePublished":"2024-07-18T15:04:30+00:00","dateModified":"2025-01-14T17:18:57+00:00","mainEntityOfPage":{"@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/"},"wordCount":398,"publisher":{"@id":"https:\/\/capahc.com\/#organization"},"image":{"@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#primaryimage"},"thumbnailUrl":"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp","articleSection":["NOUVELLES ET ARTICLES"],"inLanguage":"en-CA"},{"@type":"WebPage","@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/","url":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/","name":"Hep C new treatment access Quebec - CAPAHC","isPartOf":{"@id":"https:\/\/capahc.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#primaryimage"},"image":{"@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#primaryimage"},"thumbnailUrl":"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp","datePublished":"2024-07-18T15:04:30+00:00","dateModified":"2025-01-14T17:18:57+00:00","description":"Acc\u00e8s \u00e9largi aux traitements de l'h\u00e9patite C au Qu\u00e9bec. Harvoni et Holkira Pak rembours\u00e9s. Taux de gu\u00e9rison \u00e9lev\u00e9s. Traitement plus court.","breadcrumb":{"@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/"]}]},{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#primaryimage","url":"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp","contentUrl":"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/harvoni-in-fingers.webp"},{"@type":"BreadcrumbList","@id":"https:\/\/capahc.com\/hep-c-new-treatment-access-quebec\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/capahc.com\/"},{"@type":"ListItem","position":2,"name":"Hep C new treatment access Quebec"}]},{"@type":"WebSite","@id":"https:\/\/capahc.com\/#website","url":"https:\/\/capahc.com\/","name":"CAPAHC","description":"Your reference for hepatitis C in Quebec","publisher":{"@id":"https:\/\/capahc.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/capahc.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/capahc.com\/#organization","name":"CAPAHC - Centre Associatif Polyvalent d\u2019Aide H\u00e9patite C","url":"https:\/\/capahc.com\/","logo":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capahc.com\/#\/schema\/logo\/image\/","url":"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/Logo-CAPAHC-.webp","contentUrl":"https:\/\/capahc.com\/wp-content\/uploads\/2024\/12\/Logo-CAPAHC-.webp","width":672,"height":133,"caption":"CAPAHC - Centre Associatif Polyvalent d\u2019Aide H\u00e9patite C"},"image":{"@id":"https:\/\/capahc.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CAPAHC","https:\/\/ca.linkedin.com\/company\/capahc","https:\/\/www.youtube.com\/channel\/UCBZzrLKLNGiWTqCuQEY95xA","https:\/\/www.instagram.com\/capahcorg"]},{"@type":"Person","@id":"https:\/\/capahc.com\/#\/schema\/person\/422fdb9132c4ee6be40a85ed2d59f15e","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/capahc.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/cb4c1630c77eb892adbde4044bcc33d61d3408dafde03675d45b78038e160d85?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cb4c1630c77eb892adbde4044bcc33d61d3408dafde03675d45b78038e160d85?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/capahc.com"],"url":"https:\/\/capahc.com\/en\/author\/admin\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/posts\/2896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/comments?post=2896"}],"version-history":[{"count":0,"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/posts\/2896\/revisions"}],"wp:attachment":[{"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/media?parent=2896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/categories?post=2896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/capahc.com\/en\/wp-json\/wp\/v2\/tags?post=2896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}